Neuphoria Therapeutics (NEUP) Receivables - Other (2020 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Receivables - Other for 5 consecutive years, with $488372.0 as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Other rose 24064.87% to $488372.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $488372.0, a 24064.87% increase, with the full-year FY2023 number at $596.65, down 98.04% from a year prior.
- Receivables - Other was $488372.0 for Q4 2025 at Neuphoria Therapeutics, up from $1758.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $488372.0 in Q4 2025 to a low of $592.17 in Q2 2023.
- A 4-year average of $75336.6 and a median of $2021.0 in 2024 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: tumbled 98.05% in 2023, then skyrocketed 24064.87% in 2025.
- Neuphoria Therapeutics' Receivables - Other stood at $30429.2 in 2022, then crashed by 98.05% to $592.17 in 2023, then soared by 241.29% to $2021.0 in 2024, then surged by 24064.87% to $488372.0 in 2025.
- Per Business Quant, the three most recent readings for NEUP's Receivables - Other are $488372.0 (Q4 2025), $1758.0 (Q3 2025), and $2908.0 (Q1 2025).